Meta‐analysis: comparative efficacy of different proton‐pump inhibitors in triple therapy for Helicobacter pylori eradication

Abstract

SUMMARYBackground: It is not known whether certain protonpump inhibitors are more efficacious than others when used in triple therapy for Helicobacter pylori eradication. Aim: To compare the efficacy of different proton-pump inhibitors in triple therapy by performing a meta-analysis. Methods: A MEDLINE search was performed. Abstracts of the European Helicobacter pylori Study Group and the American Gastroenterological Association congresses from 1996 to 2002 were also examined. Randomized studies with at least two branches of triple therapy that differed only in terms of type of proton-pump inhibitor were included in a meta-analysis using Review Manager 4.1.

Use of probiotics as an adjuvant to sequential H. pylori eradication therapy: impact on eradication rates, treatment resistance, treatment-related side effects, and patient compliance

“…The beneficial effects of Lactobacillus-and Bifidobacterium-containing probiotics on the eradication rate and the incidence of total side effects during H. pylori eradication therapy has also been reported in a meta-analysis by Wang et al (29) Hence, the eradication rates obtained in the placebo group in our cohort are consistent with the overall eradication rates reported previously in randomized trials (3,39,44), while the benefit of probiotic therapy on eradication rates also seems to be in agreement with data from studies on probiotics (18,25,29,30,39,(45)(46)(47), including Bifidobacterium (17,42,45).…”

“…However, similar tendencies of decline in eradication rates have also been reported in recent studies with these alternative regimens because of increased antibiotic resistance as well as increased incidence of undesirable side effects of longer term treatment, which can lead to patient non-compliance (2,3,6,7,(12)(13)(14).…”

Five-Year Examination of Utilization and Drug Cost Outcomes Associated with Benefit Design Changes Including Reference Pricing for Proton Pump Inhibitors in a State Employee Health Plan

“…[4][5][6][7] The literature review showed that the PPIs are a particularly well-tolerated class of drugs. Using this evidence, the DUEC concluded that all PPIs were therapeutically equivalent in efficacy and safety.…”

Effects on the Cost and Utilization of Proton Pump Inhibitors From Adding Over-the Counter Omeprazole to Drug Benefit Coverage in a State Employee Health Plan

“…Systematic reviews have compared clinical efficacy of equipotent doses of available PPIs for symptomatic relief and the maintenance of healing in gastroesophageal reflux disease (GERD), for the healing and maintenance of healing in gastric and duodenal ulcers, and in combination with antibiotic regimens for Helicobactor pylori eradication. [9][10][11] The data consistently support that omeprazole 20 mg is similar in efficacy to lansoprazole (Prevacid) 30 mg, pantoprazole (Protonix) 40 mg, and rabeprazole (Aciphex) 20 mg.…”